Effects of nano curcumin supplementation on the reduction of inflammation and mortality in patients with coronavirus 2019 admitted to ICU ward of imam Reza hospital in Tabriz

Phase 2

Recruiting

Conditions: COVID-2019.
COVID-19, virus identified
U07.1

Registration Number: IRCT20200324046851N1

Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 86

Inclusion Criteria

Confirmation of positive for coronavirus by RT-pcr
Willingness to cooperate
In accordance with clinical diagnosis or etiologic criteria for coronavirus pneumonia (COVID-19).
Able to sign informed consent

Exclusion Criteria

Nutrition and antioxidant supplements and alpha lipoic acid during one month before study
Pregnancy and lactation
Severe immune suppression (HIV infection, long-term use of immunosuppressive agents)
Unwillingness to continue cooperation

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Expression of peripheral blood mononuclear cell (PBMC)- Genes Expressed in Nano-Curcumin Patients with Control Group (Before and After Treatment). Timepoint: At baseline and 14 days later. Method of measurement: Real time Polymerase chain reaction.;The secretion rate of peripheral blood mononuclear cell (PBMC)-treated cytokines in nano-curcumin patients and control group (before and after treatment). Timepoint: At baseline and 14 days later. Method of measurement: Elisa kit.;Clinical features. Timepoint: At baseline and 14 days later. Method of measurement: Clinical observations by specialists.;Laboratory observations. Timepoint: At baseline and 14 days later. Method of measurement: Review by a pulmonary specialist.

Secondary Outcome Measures